Nov 2015

Drug Discovery Innovation Programme (November 25-26, 2015)

Dr. Noam Emanuel, PolyPid’s Chief Technology Officer, will present at the Drug Discovery Innovation Programme (DDIP), to be held on November 25-26, 2015 in Munich, Germany. Dr. Emanuel's presentation title will be: "PLEX™ Local Drug Delivery Platform Enables Prolonged, Controlled-Release Medications".

Oct 2015

Go4Israel International Business Conference (October 26, 2015)

Dikla Czaczkes Akselbrad, PolyPid’s Chief Strategy Officer, will sit on the Biotech panel at the Go4Israel International Business Conference, to be held on October 26, 2015, at the Hilton hotel in Tel Aviv, Israel.

Sep 2015

34th European Bone and Joint Infection Society (September 10-12, 2015)

PolyPid’s and AO foundation’s joint study, as part of the BALI consortium, was included among the top 10 rated abstracts of the European Bone and Joint Infection Society (EBJIS) annual meeting, to be held on September 10-12, 2015 in Estoril, Lisboa, Portugal. The study, titled “Prevention of implant-related osteomyelitis due to doxycycline-resistant MRSA using a doxycycline-loaded polymer-lipid encapsulation matrix coating” will be presented by AO foundation.

Jun 2015

eCM XVI: Implant Infection (June 24-26, 2015)

Dr. Noam Emanuel, PolyPid’s Chief Technology Officer, will present at eCM XVI: Implant Infection (Orthopaedic & Musculoskeletal Trauma related), to be held June 24-26, 2015 at the Congress Center, Davos, Switzerland. Dr. Emanuel’s presentation is titled “Efficacy of a Lipid-and-Polymer-based Drug Delivery Coating Containing Doxycycline for the Prevention of Implant-related Osteomyelitis.”

Jun 2015

The 2015 BIO International Convention (June 15-18, 2015)

Mr. Amir Weisberg, PolyPid’s CEO and Mr. Asaf Bar, PolyPid’s CBO, will participate at the 2015 BIO International Convention to be held June 15-18, 2015 at the Pennsylvania Convention Center, Philadelphia, Pennsylvania, USA.

May 2015

The 16th EFFORT (European Federation of National Associations of Orthopaedics and Traumatology) Congress (May 27-29, 2015)

PolyPid’s abstract “Prevention Of Implant-Related Osteomyelitis Using A Doxycycline Coating In A Humeral Non-Fracture Rabbit Model” was accepted to be included in the scientific program of the upcoming 16th EFFORT (European Federation of National Associations of Orthopaedics and Traumatology) Congress, which will be held in Prague, Czech Republic on  27-29 of May 2015. The abstract will be presented by our partners, the AO foundation.

May 2015

IATI BioMed – Biomed Israel 2015 (May 12-14, 2015)

PolyPid will participate at IATI BioMed (Biomed Israel 2015), Israel’s 14th National Life Sciences & technology Week, to be held May 12-14, 2015, at the Tel Aviv Convention Center, Israel.

Mar 2015

AAOS Annual Meeting (March 24-28, 2015)

Mr. Amir Weisberg, PolyPid’s CEO, and Mr. Asaf Bar, PolyPid’s CBO, will participate at the annual meeting of the American Academy of Orthopaedic Surgeons, to be held March 24-28, 2015 at the Venetian/Sands EXPO Center in Las Vegas, Nevada, USA. They will meet with doctors, thought leaders, and companies.

Jul 2014

The 22nd Annual Meeting of the European Orthopaedic Research Society (EORS) (July 2-4, 2014)

Dr. Noam Emanuel, PolyPid’s Chief Technology Officer, presented PolyPid at the 22nd annual meeting of the European Orthopaedic Research Society (EORS), held  at Nantes Events Center, Nantes, France, July 2-4, 2014. Dr. Emanuel’s presentation, titled “Efficacy of a lipid-and-polymer-based PolyPid drug delivery coating containing doxycycline to prevent implant-related infection”, was held on July 2, 2014 at the Implant Surface Modifications session.

Jun 2014

Bio International Convention (June 23-26, 2014)

Mr. Amir Weisberg and Mr. Asaf Bar will present PolyPid and its technology as part of the Israeli pavilion at the 2014 Bio International Convention,to be held at the San Diego Convention Center, San Diego, California, June 23-26, 2014.

Technology

The PLEX™ (Polymer-Lipid Encapsulation matriX) platform is a matrix made of alternating layers of polymers and lipids that allows controlled, local release of unmodified drugs over extended periods of time.

Read More >

D-PLEX100

Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >

D-PLEX1000

Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >